Palatin Technologies plans to move two obesity-targeting drugs — experimental therapies designed to activate the melanocortin-4 receptor (MC4R) protein, which is involved in appetite and energy balance — into clinical testing in people with Prader-Willi syndrome (PWS) this year. Planned trials will also test the company’s candidates in…
An ongoing, global clinical trial testing Aardvark Therapeutics’ ARD-101 for hyperphagia, or excessive hunger, in people with Prader-Willi syndrome (PWS) has lowered the minimum enrollment age in the U.S. to allow children as young as 7 to take part, according to a study update. The Phase 3…
Discussion
February has two different meanings for our family. On one hand, it’s the month of roses, chocolates, cards, and heart-shaped everything. On the other, it’s Rare Disease Awareness Month, culminating in Rare Disease Day on Feb. 28. It’s a time when families like ours, who are living with…
Prader-Will syndrome is a rare and complex genetic condition that results in a variety of physical and mental symptoms. Learn more about the disease here.
Prader-Willi is caused by genetic changes in a particular area of chromosome 15. Learn more about what causes the disease here.
Symptoms of Prader-Willi range from physical impairments to cognitive and behavioral issues. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
